Go Pro
→ Trump and Bernie agree on this (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$11.47
+5.8%		$10.43
$8.56
▼
$14.76
$63.29M0.2614,110 shs69,771 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$5.81
+6.6%		$4.47
$9.41
▼
$13.80
$65.14M0.09205,918 shs761,615 shs
HeartSciences Inc. stock logo
HSCS
HeartSciences
$3.39
-3.4%		$2.67
$1.63
▼
$4.35
$13.69M1.85153,975 shs100,657 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$1.54
+2.7%		$1.56
$1.26
▼
$6.87
$58.14M1.63542,292 shs179,274 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
+5.81%+11.68%+12.45%+15.35%+0.88%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
+6.61%+22.57%+32.05%+41.71%+114.39%
HeartSciences Inc. stock logo
HSCS
HeartSciences
-3.42%-9.12%+69.50%+88.33%+2.42%
Nyxoah SA stock logo
NYXH
Nyxoah
+2.67%-4.94%-2.53%+10.79%-72.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$11.47
+5.8%		$10.43
$8.56
▼
$14.76
$63.29M0.2614,110 shs69,771 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$5.81
+6.6%		$4.47
$9.41
▼
$13.80
$65.14M0.09205,918 shs761,615 shs
HeartSciences Inc. stock logo
HSCS
HeartSciences
$3.39
-3.4%		$2.67
$1.63
▼
$4.35
$13.69M1.85153,975 shs100,657 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$1.54
+2.7%		$1.56
$1.26
▼
$6.87
$58.14M1.63542,292 shs179,274 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
+5.81%+11.68%+12.45%+15.35%+0.88%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
+6.61%+22.57%+32.05%+41.71%+114.39%
HeartSciences Inc. stock logo
HSCS
HeartSciences
-3.42%-9.12%+69.50%+88.33%+2.42%
Nyxoah SA stock logo
NYXH
Nyxoah
+2.67%-4.94%-2.53%+10.79%-72.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daxor Corporation stock logo
DXR
Daxor
2.50
Moderate BuyN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
0.00
N/AN/AN/A
HeartSciences Inc. stock logo
HSCS
HeartSciences
2.00
Hold$8.00135.99% Upside
Nyxoah SA stock logo
NYXH
Nyxoah
2.25
Hold$4.26176.75% Upside

Current Analyst Ratings Breakdown

Latest HSCS, DXR, HSAQ, and NYXH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/17/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$6.00
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$2.31
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$7.00 ➝ $6.00
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$4.00
7/9/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$2.85
6/24/2026
Daxor Corporation stock logo
DXR
Daxor
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
6/24/2026
HeartSciences Inc. stock logo
HSCS
HeartSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/17/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$5.00 ➝ $3.00
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/A($0.62) per shareN/A
HeartSciences Inc. stock logo
HSCS
HeartSciences
N/AN/AN/AN/A$0.07 per shareN/A
Nyxoah SA stock logo
NYXH
Nyxoah
$11.33M5.27N/AN/A$1.43 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
-$380KN/AN/AN/AN/AN/AN/A-2.38%N/A
HeartSciences Inc. stock logo
HSCS
HeartSciences
-$9.14M-$3.94N/AN/AN/AN/A-358.60%-144.82%N/A
Nyxoah SA stock logo
NYXH
Nyxoah
-$101.92M-$2.52N/AN/AN/A-443.16%-178.90%-81.83%11/5/2026 (Estimated)

Latest HSCS, DXR, HSAQ, and NYXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.47-$0.67-$0.20-$0.66$8.64 million$8.76 million
7/23/2026Q4 2026
HeartSciences Inc. stock logo
HSCS
HeartSciences
-$0.66-$0.88-$0.22-$0.87$0.05 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/AN/A
HeartSciences Inc. stock logo
HSCS
HeartSciences
N/AN/AN/AN/AN/A
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/A
0.17
0.61
HeartSciences Inc. stock logo
HSCS
HeartSciences
N/A
0.53
0.40
Nyxoah SA stock logo
NYXH
Nyxoah
0.44
2.38
2.31

Institutional Ownership

CompanyInstitutional Ownership
Daxor Corporation stock logo
DXR
Daxor
1.34%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
89.71%
HeartSciences Inc. stock logo
HSCS
HeartSciences
17.24%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A

Insider Ownership

CompanyInsider Ownership
Daxor Corporation stock logo
DXR
Daxor
51.50%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
21.90%
HeartSciences Inc. stock logo
HSCS
HeartSciences
4.90%
Nyxoah SA stock logo
NYXH
Nyxoah
17.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Daxor Corporation stock logo
DXR
Daxor
375.84 million2.83 millionNot Optionable
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
411.21 million8.76 millionNot Optionable
HeartSciences Inc. stock logo
HSCS
HeartSciences
103.90 million3.71 millionNot Optionable
Nyxoah SA stock logo
NYXH
Nyxoah
11038.76 million32.13 millionNot Optionable

Recent News About These Companies

Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?
September 10 at 6:31 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/nyxoah-nyxh-begins-breathe-study-can-real-world-evidence-drive-genio-adoption-1834505/
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption?
September 10 at 6:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nyxoah-nyxh-begins-breathe-study-211832079.html
Nyxoah stock down despite first Genio implant in US Breathe trial
September 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/nyxoah-stock-down-despite-first-genio-implant-in-us-breathe-trial/ar-AA2bOO4Y
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986514/nyxoah-stock-down-despite-first-genio-implant-in-u-s-breathe-trial?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2986514
Nyxoah Implants First Patient in Sleep Apnea Device Study
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nyxoah-implants-first-patient-sleep-085107175.html
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®
September 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/07/3357261/0/fr/nyxoah-annonce-l-implantation-du-premier-patient-dans-breathe-l-%c3%a9tude-post-approbation-am%c3%a9ricaine-du-syst%c3%a8me-genio.html
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
September 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/07/3357261/0/en/nyxoah-announces-first-patient-implanted-in-breathe-the-u-s-post-approval-study-of-the-genio-system.html
Nyxoah rises as trial win for Genio boosts case for label expansion
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/nyxoah-rises-as-trial-win-for-genio-boosts-case-for-label-expansion/ar-AA2bw38o
Nyxoah's ACCCESS Trial Of Genio System Meets Primary Goals In CCC Sleep Apnea Patients; Shares Jump
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688057/nyxoah-s-acccess-trial-of-genio-system-meets-primary-goals-in-ccc-sleep-apnea-patients-shares-jump.aspx
Nyxoah Shares Jump After Genio Meets Primary Endpoints in CCC Patient Study
September 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nyxoah-shares-jump-genio-meets-214823144.html
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
September 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nyxoah-announces-acccess-u-s-pivotal-study-meets-primary-safety-and-efficacy-endpoints-in-complete-concentric-collapse-patients-1036517105
Nyxoah Updates Share Count and Potential Dilution From Convertible Instruments
August 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nyxoah-updates-share-count-and-potential-dilution-from-convertible-instruments?utm_source=marketbeat.com&utm_medium=referral
Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cantor-fitzgerald-issues-pessimistic-forecast-for-nyxoah-nasdaqnyxh-stock-price-2026-08-17/
Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931411-nyxoah-sa-nyxh-q2-2026-earnings-call-transcript
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339674/0/en/nyxoah-reports-second-quarter-and-first-half-2026-financial-and-operating-results.html
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333855/0/en/nyxoah-to-release-second-quarter-2026-financial-results-on-august-5-2026.html
Nyxoah touts Genio US launch traction, reimbursement stability at investor day
July 11, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/nyxoah-touts-genio-us-launch-traction-reimbursement-stability-at-investor-day/ar-AA27FKRx
Nyxoah SA (NYXH) Analyst/Investor Day Transcript
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920699-nyxoah-sa-nyxh-analyst-investor-day-transcript
Nyxoah (ENXTBR:NYXH) Stock Fair Value Moves Lower After Capital Raise And Analyst Caution
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/nyxoah-enxtbr-nyxh-stock-fair-091502439.html
Nyxoah reports Q2 2026 preliminary revenue of €7.7M
July 7, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/nyxoah-reports-q2-2026-preliminary-revenue-of-77m/ar-AA27q7EB
Nyxoah Announces Preliminary Results for the Second Quarter of 2026
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323627/0/en/nyxoah-announces-preliminary-results-for-the-second-quarter-of-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Daxor stock logo

Daxor NASDAQ:DXR

$11.47 +0.63 (+5.81%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$11.40 -0.07 (-0.57%)
As of 09/11/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Health Sciences Acquisitions Co. 2 stock logo

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$5.81 +0.36 (+6.61%)
As of 09/10/2026

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

HeartSciences stock logo

HeartSciences NASDAQ:HSCS

$3.39 -0.12 (-3.42%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$3.50 +0.11 (+3.22%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Nyxoah stock logo

Nyxoah NASDAQ:NYXH

$1.54 +0.04 (+2.67%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.50 -0.04 (-2.53%)
As of 09/11/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas